PlainRecalls
FDA Drug Critical Class I Terminated

IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.

Reported: April 20, 2022 Initiated: March 29, 2022 #D-0765-2022

Product Description

IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.

Reason for Recall

Presence of Particulate Matter: Product was found to contain silica and iron oxide

Details

Units Affected
1565 vials
Distribution
Nationwide within the United States
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.. Recalled by Teva Pharmaceuticals USA Inc. Units affected: 1565 vials.
Why was this product recalled?
Presence of Particulate Matter: Product was found to contain silica and iron oxide
Which agency issued this recall?
This recall was issued by the FDA Drug on April 20, 2022. Severity: Critical. Recall number: D-0765-2022.